Information needs and decision making preferences of older women offered a choice between surgery and primary endocrine therapy for early breast cancer

ConclusionsWomen strongly preferred face to face information. Written formats were also helpful, but not computer based resources. Information that was found helpful to women in the DM process was identified. The study demonstrates many women achieved their preferred DM style, with a preference for involvement, and expressed low levels of decision regret.
Source: Psycho-Oncology - Category: Cancer & Oncology Authors: Tags: PAPER Source Type: research

Related Links:

This review summarizes the role and rationale of fulvestrant when used as a monotherapy or in combination with targeted therapies in patients with HR+/HER2 − advanced breast cancer. We also discuss other novel agents and potential future combination treatment options. AbstractNearly 75% of breast cancers are hormone receptor ‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the clinic, endocrine resistance (p...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
ConclusionThis screening tool identified geriatric syndromes requiring attention in many patients with breast cancer presenting for medical oncology appointments. In oncology practice, need for referral networks to address geriatric syndromes should be assessed.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Conditions:   Breast Cancer Female;   Hormone Receptor Positive Tumor Intervention:   Drug: Tamoxifen Citrate Sponsors:   British Columbia Cancer Agency;   Canadian Cancer Society Research Institute (CCSRI);   NanoString Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: This study showed that the 21-gene RS assay was not able to predict the benefit of PMRT for OS in women with T1-2 N1mic ER-positive HER2-negative breast cancer. However, further prospective larger sample-size trials are warranted to determine if a benefit exists. Introduction According to the latest Global Cancer Statistics 2018, breast cancer is still the most frequent cancer and the leading cause of cancer death among females worldwide (1). It is estimated that there will be about 2.1 million newly diagnosed female breast cancer cases and 627,000 cancer death in 2018 (1). The use of screening tests for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract OBJECTIVE: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. METHODS: DNA from FFPE tumor tissue obtained during routine clinical care for 9645 gynecologic malignancies (ovary, fallopian tube, uterus, cervix, vagina, vulvar, and placenta) was anal...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Cancers, Vol. 11, Pages 526: Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR+/HER2− Breast Cancer Cancers doi: 10.3390/cancers11040526 Authors: Guo Tada Kitamura Hamada Miyashita Harada-Shoji Sato Hamanaka Tsuboi Harada Takano-Kasuya Okada Nakano Ohuchi Hayashi Ishida Gonda In addition to genomic signaling, Estrogen receptor alpha (ERα) is associated with cell proliferation and survival through extranuclear signaling contributing to endocrine therapy (ET) resistance. H...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Abstract BACKGROUND: Despite advances in therapies to treat breast cancer, over 100,000 patients die in the UK of this disease per year, highlighting the need to develop effect predictive and prognostic markers for patients with primary operable ductal breast cancer. Therefore, the aim of the present study was to examine the relationship between membranous, cytoplasmic and nuclear expression of focal adhesion kinase (phosphorylated at Y 397, Y 861 and Y 925), molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. METHODS: Four hundred and seventy-four ...
Source: Cellular Signalling - Category: Cytology Authors: Tags: Cell Signal Source Type: research
This study evaluated the association between BRCA mutation status and serum anti-Müllerian hormone (AMH) level in young, reproductive-aged patients with breast cancer. Materials and Methods: Patients ≤ 40 years of age with breast cancer and who had known BRCA status and baseline serum AMH level at Samsung Medical Center, Seoul, Korea, were considered for inclusion. A total of 52 BRCA mutation carriers (27 BRCA1 and 25 BRCA2) and 264 non-carriers were selected for analyses. The serum level of AMH was compared according to presence of a BRCA mutation, and linear and logistic regression analyses were performed to eva...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Computers | Endocrine Therapy | Nurses | Nursing | Study | Women